Sector News

Chr. Hansen and Novozymes announce merger

December 17, 2022
Life sciences

Danish enzyme producers Chr. Hansen and Novozymes have entered into an agreement to merge, with the aim of creating a global leader in biosolutions.

Chr. Hansen develops ingredients for the food, pharmaceutical and agricultural industries, including cultures, enzymes and probiotics, while Novozymes describes itself as “the world’s largest provider of enzyme and microbial technologies”.

Ester Baiget, president and CEO of Novozymes, said: “The combination of two strategically complementary companies with a shared purpose and advanced capabilities will show the world the true power of biosolutions”.

She added: “Novozymes and Chr. Hansen share the strong conviction that our combined scale, know-how, commercial strengths and innovation excellence will drive value for our shareholders, customers and society at large by providing the sustainable solutions the world so urgently needs”.

Offering a broad “biological toolbox,” the combined company is expected to have annual revenue of approximately €3.5 billion. With around 10,000 employees, the biosolutions group will operate a global network of 23 manufacturing sites and 38 R&D and application centres.

Novo Holdings is the largest shareholder in both Novozymes and Chr. Hansen. Chairman Lars Rebien Sørensen said: “The two companies are a perfect match. Chr. Hansen with its expertise in microbials and Novozymes with its background in enzymes.”

Upon completion of the merger, Baiget will assume leadership of the combined group as CEO, while Novozymes’ current finance chief, Lars Green, will be CFO.

The merger is contingent on approvals via extraordinary general meetings of the two companies, as well as regulatory approvals. The deal is currently expected to be completed in the fourth quarter of next year or first quarter of 2024.

By Antonia Garrett Peel


comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach